STOCK TITAN

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2022 Financial Results on August 9, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Organogenesis Holdings Inc. (Nasdaq: ORGO) announced its second quarter fiscal year 2022 financial results will be released after market close on August 9, 2022. A conference call will follow at 5:00 p.m. Eastern Time, providing an overview of the results and corporate updates. Interested participants can access the live webcast through the company's investor relations website. The archived version will also be available for roughly one year. Organogenesis specializes in regenerative medicine, focusing on products for Advanced Wound Care and Surgical & Sports Medicine.

Positive
  • Organogenesis is a leader in regenerative medicine with a comprehensive portfolio for advanced wound care and surgical applications.
Negative
  • None.

CANTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2022 financial results will be reported after the market closes on Tuesday, August 9th.

Management will host a conference call at 5:00 p.m. Eastern Time on August 9th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.


FAQ

When will Organogenesis report its second quarter fiscal year 2022 financial results?

Organogenesis will report its second quarter fiscal year 2022 financial results after market close on August 9, 2022.

What time is the Organogenesis conference call scheduled for?

The conference call is scheduled for 5:00 p.m. Eastern Time on August 9, 2022.

Where can I access the live webcast of the Organogenesis conference call?

The live webcast can be accessed via the company’s investor relations website.

What is the focus of Organogenesis Holdings Inc.?

Organogenesis focuses on developing product solutions for Advanced Wound Care and Surgical & Sports Medicine markets.

Organogenesis Holdings Inc.

NASDAQ:ORGO

ORGO Rankings

ORGO Latest News

ORGO Stock Data

430.21M
74.14M
43.44%
48.28%
7.85%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
CANTON